IgA Nephropathy News and Research

RSS

IgA nephropathy (IgAN), also known as Berger’s disease, is the leading cause of primary glomerulonephritis all over the world. It is autoimmune in origin, characterized by the stimulation of genetically determined formation of concentration of IgA1 with galactose-deficient O-glycans in the hinge-region (Hit 1) in the blood. These stimulate anti-glycan antibody production, followed by binding with the aberrantly glycated IgA1.

6th CKD Drug Development Summit: Countdown Begins

...

From 6th CKD Drug Development Summit 16 Feb 2024

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Do prebiotics and probiotics positively impact cardiovascular and renal health?

The benefits of consuming nutrients, prebiotics, and probiotics to enhance cardiovascular and renal health.

11 Oct 2023

Study supports vaccination for COVID-19 in patients with glomerular diseases

Among 2,055 adults with a wide range of glomerular diseases, the COVID-19 vaccination did not adversely affect kidney function or worsen kidney damage and appeared safe in this population.

5 Sep 2023

IgA nephropathy: The disease that lies outside the kidney

The cause of a common kidney disease likely lies outside the kidney, according to a new study led by Columbia University researchers.

23 Jun 2023

$New facile strategy for proteome analysis using ultracentrifugation fractionation$

New facile strategy for proteome analysis using ultracentrifugation fractionation

Urine is one of the attractive sources for early and sensitive biomarker discovery since it can accumulate and reflect changes in the human body while being collected non-invasively.

16 Jun 2023

Study finds low absolute risk of glomerular disease relapse associated with COVID-19 vaccination

Several reports have described a relapse of certain autoimmune kidney diseases in patients after they've received COVID-19 vaccines, but it's unclear if this association is real or a coincidence.

4 Nov 2022

Adults with primary glomerular disease have high cardiovascular risk, study shows

Among almost 2,000 adults with primary glomerular disease followed for a median of 6.8 years, risk of cardiovascular events including coronary artery, cerebrovascular, and peripheral vascular events, and death due to myocardial infarction or stroke was 2.5-fold higher compared to the general population.

1 Jun 2022

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

In a recent study posted to the medRxiv* pre-print server, researchers assessed whether messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines increase the incidence of glomerulonephritis against the null hypothesis stating any observed temporal association between the two phenomena was purely coincidental.

26 May 2022

Multi-country study provides a clear treatment option for IgA nephropathy

The largest ever randomized controlled trial in IgA nephropathy has found that treatment with methylprednisolone - a cheap, widely used corticosteroid drug - halves the risk of losing kidney function and kidney failure, and that this can be effectively achieved with fewer side effects if a reduced dose is used.

17 May 2022

Pioneering kidney disease research at Leicester receives a major boost on World Kidney Day

Pioneering research by the University of Leicester into chronic kidney disease has received a major boost on World Kidney Day (10th March 2022) following a generous £1million donation from long-term supporter and kidney health advocate Jimmy Mayer.

10 Mar 2022

Study evaluates the potential benefits of mass dipstick screening to detect hematuria

As the saying goes, "the sooner the better," and such is the case for the detection of kidney and urological diseases. Early detection is key, and may be achieved through the use of a dipstick urine test.

4 Feb 2022

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Study reports safety, efficacy of targeted treatment for IgA nephropathy

IgA nephropathy (IgAN) is a chronic kidney disease occurring in young adults and is one of the most common reasons for kidney transplantation in this age group.

7 Jun 2021

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020